Evolving Standards in Multiple Myeloma Management: Critical Updates From the 2025 NCCN Guidelines : Episode 1
Opinion
Video
Early Intervention and Personalized Frontline Therapies in Multiple Myeloma
Author(s):
A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial therapy choices between triplet and quadruplet regimens.
Video content above is prompted by the following:
- How are you approaching patients with high-risk smoldering multiple myeloma, particularly in considering early intervention before traditional CRAB (hypercalcemia, renal dysfunction, anemia, bone disease) criteria are met?
- What is your approach to personalizing first-line therapy selection among VRd (bortezomib, lenalidomide, and dexamethasone), KRd (carfilzomib, lenalidomide, and dexamethasone), and Dara-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone), considering the emerging quadruplet regimens?
Related Videos
Related Content
